Trial Profile
Randomized Double-Blind Phase 2 Trial Of RAD001 For Neurocognition In Individuals With Tuberous Sclerosis Complex
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Cognition disorders; Tuberous sclerosis
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 23 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 29 Jul 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.